1. Home
  2. BGSF vs GRML Comparison

BGSF vs GRML Comparison

Compare BGSF & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BGSF Inc.

BGSF

BGSF Inc.

HOLD

Current Price

$5.53

Market Cap

55.0M

ML Signal

HOLD

GRML

Greenland Mines Ltd. Common Stock

N/A

Current Price

$0.26

Market Cap

51.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
BGSF
GRML
Founded
2007
N/A
Country
United States
United States
Employees
N/A
5
Industry
Professional Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
55.0M
51.5M
IPO Year
2013
2022

Fundamental Metrics

Financial Performance
Metric
BGSF
GRML
Price
$5.53
$0.26
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
12.6K
3.4M
Earning Date
05-06-2026
05-13-2026
Dividend Yield
36.04%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$93,310,000.00
N/A
Revenue This Year
$4.67
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.26
$0.27
52 Week High
$8.20
$0.55

Technical Indicators

Market Signals
Indicator
BGSF
GRML
Relative Strength Index (RSI) 60.67 31.62
Support Level $5.49 N/A
Resistance Level $5.79 $0.44
Average True Range (ATR) 0.18 0.03
MACD 0.06 -0.00
Stochastic Oscillator 90.65 3.66

Price Performance

Historical Comparison
BGSF
GRML

About BGSF BGSF Inc.

BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. The company operates in one segment of Property Management, which includes centralized support services through executive, marketing, human resources, information technology, accounting, treasury, and billing operations.

About GRML Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Share on Social Networks: